Cilastatin/imipenem/relebactam - Merck Sharp and Dohme
Alternative Names: Cilastatin/relebactam/imipenem; IMI/REL; Imipenem/cilastatin/relebactam; Imipenem/relebactam/cilastatin; MK-7655A; RECARBRIO; Relebactam + imepenem/cilastatin; Relebactam/cilastatin/imipenem; Relebactam/imipenem/cilastatinLatest Information Update: 07 Jun 2024
At a glance
- Originator Merck Sharp & Dohme
- Class Anti-infectives; Antibacterials; Azabicyclo compounds; Carbapenems; Cyclopropanes; Piperidines; Small molecules; Thienamycins
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Exopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
- Registered Bacteraemia; Bacterial infections
- Phase II/III Gram-negative infections
- No development reported Sepsis
Most Recent Events
- 07 May 2024 Merck completes the phase II/III trials in Gram-negative infections (In adolescents, In children, In infants, In neonates) in US, Colombia, Poland, France, South Africa, Russia, Bulgaria, Chile, Estonia, Greece, Hungary, Israel, Mexico, Norway, Philippines, Spain, Turkey and Ukraine (IV) (NCT03969901)
- 11 Oct 2023 Efficacy and adverse events data from a phase III trial in Nosocomial pneumonia and Ventilator-associated-pneumonia presented at the IDWeek 2023 (IDW-2023)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Gram-negative-infections(In adolescents, In children, In infants, In neonates) in Bulgaria (IV, Infusion)